Dwight Moxie
Net Worth
Last updated:
What is Dwight Moxie net worth?
The estimated net worth of Mr. Dwight Moxie is at least $4,968,630 as of 6 Sep 2023. He owns shares worth $160,841 as insider, has earned $2,284,229 from insider trading and has received compensation worth at least $2,523,560 in Revance Therapeutics, Inc..
What is the salary of Dwight Moxie?
Mr. Dwight Moxie salary is $630,890 per year as Senior Vice President, Gen. Counsel & Corporation Sec. in Revance Therapeutics, Inc..
How old is Dwight Moxie?
Mr. Dwight Moxie is 48 years old, born in 1977.
What stocks does Dwight Moxie currently own?
As insider, Mr. Dwight Moxie owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Revance Therapeutics, Inc. (RVNC) | Senior Vice President, Gen. Counsel & Corporation Sec. | 44,066 | $3.65 | $160,841 |
What does Revance Therapeutics, Inc. do?
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DaxibotulinumtoxinA in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Dwight Moxie insider trading
Revance Therapeutics, Inc.
Mr. Dwight Moxie has made 6 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 11,000 units of RVNC stock worth $187,704 on 6 Sep 2023.
The largest trade he's ever made was exercising 23,853 units of RVNC stock on 5 Sep 2023. As of 6 Sep 2023 he still owns at least 44,066 units of RVNC stock.
Revance Therapeutics key executives
Revance Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Dr. Abhay Joshi (62) Chief Operating Officer, Pres of R&D and Product Operations
- Mr. Dustin S. Sjuts (46) Pres
- Mr. Dwight Moxie (48) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Mark J. Foley (60) Chief Executive Officer & Director
- Mr. Tobin C. Schilke (50) Chief Financial Officer & Principal Accounting Officer